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~75% of patients with late stage breast cancer will develop bone metastasis. This condition is 5 
currently considered incurable and patients’ life expectancy is limited to 2 3 years following 6 
diagnosis of bone involvement. IL 1B is a pro inflammatory cytokine whose expression in 7 
primary tumours has been identified as a potential biomarker for predicting breast cancer 8 
patients at increased risk for developing bone metastasis. In this Review, we discuss how IL 9 
1B from both the tumour cells and the tumour microenvironment influence growth of primary 10 
breast tumours, dissemination into the bone metastatic niche and proliferation into overt 11 
metastases. Recent evidence indicates that targeting IL 1B signalling may provide promising 12 
new treatments that can hold tumour cells in a dormant state within bone thus preventing 13 
formation of overt bone metastases.  14 
	15 
Breast cancer bone metastasis is an incurable disease. Breast cancer is the most common 16 
cause of cancer death in females in Europe and worldwide. Although the mortality rate 17 
decreased by 35% since the early 1970s, it is estimated that 1 in 8 females will develop breast 18 
cancer during their lifetime and the incidence rate is expected to increase by 2% in the UK by 19 
2035 (Cancer Research UK, Cancer Statistics, July 2017).   20 
Bone is the most common metastatic site for breast cancer and bone metastases are associated 21 
with poor prognosis and significantly reduced life expectancy to just 2 3 years following 22 
diagnosis. Patients with bone metastasis experience increased morbidity due to severe pain, 23 
reduced mobility, hypercalcemia, osteolysis and bone fractures, as well as spinal cord 24 
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compression and bone marrow aplasia. Bone pain is generally due to mechanical pressure 25 
exerted by a tumour cell mass or due to the release of inflammatory cytokines by either the 26 
tumour cells themselves or by the surrounding bone microenvironment, leading to altered 27 
bone homeostasis (Macedo, et al. 2017).  28 
The formation of breast cancer metastases in bone generally occurs in the axial skeleton, 29 
possibly in relation to high bone marrow content, where hematopoiesis actively takes place. 30 
The microenvironment is fundamental in attracting tumour cells to bone as well as promoting 31 
tumour progression. The composition of the tumour microenvironment changes during 32 
tumour development and is different at different sites (Hanahan and Weinberg 2011). This 33 
variation differently affects cancer progression as well as the efficacy of therapeutic regimes. 34 
A plethora of signalling molecules is involved in the intricate network of signalling pathways 35 
that orchestrate the communication between cancer cells and surrounding stroma. Interleukin 36 
1B (IL 1B) is a pro inflammatory cytokine whose expression in primary tumours has been 37 
identified as a potential biomarker for predicting breast cancer patients at increased risk for 38 
developing bone metastasis (Nutter, et al. 2014). 39 
Here, we provide a detailed overview of the molecular mechanisms underlying primary 40 
breast cancer development and formation of metastasis in bone, reporting recent evidence 41 
that suggest a pivotal role of IL 1B in these processes. Finally, we summarise current 42 
therapies that target the IL 1 signalling pathway that have potential to be repurposed for the 43 
treatment of metastatic breast cancer. 44 
45 
The bone is a preferred metastatic site for breast cancer cells. When tumour cells home to the 46 
bone they utilise molecular mechanisms that control the interaction between different cell 47 
types including osteoblasts, osteoclasts and hematopoietic stem cells, altering bone 48 
homeostasis to promote tumour cell survival, dormancy and/or proliferation in this 49 
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environment (Mishra, et al. 2011). In bone, the bone marrow is the main site of 50 
haematopoiesis. Because HSC self renewal and hematopoietic progenitor proliferation, 51 
commitment and differentiation occur in the same microenvironment, it is suggested that 52 
there must be different specific niches composed by different stromal cells that can regulate 53 
each step from HSC renewal to complete differentiation (Cordeiro Spinetti, et al. 2015). The 54 
bone marrow cavity can be divided into four niches: endosteal, subendosteal, central and 55 
perisinusoidal (Lambertsen and Weiss 1984; Lord, et al. 1975). HSC and multipotent 56 
progenitors are found in the endosteal and subendosteal regions, whereas committed 57 
progenitors are located in the central region and the differentiated cells in the perisinusoidal 58 
niche (Cordeiro Spinetti et al. 2015). Tumour cells home to specific regions in bone. It has 59 
been suggested that the bone microenvironment is a dynamic niche and that the formation of 60 
metastatic lesions resembles a constant osteogenesis process, allowing early stage bone 61 
colonization. During this process, adherens junctions (AJs) form between metastatic tumour 62 
cells, expressing E cadherin, and cells in the bone niche, specifically osteogenic cells, 63 
expressing N cadherin (Wang, et al. 2015). It is hypothesised that tumour cells either remain 64 
dormant or are stimulated to proliferate into overt metastases dependent on which niches they 65 
interact with: Interactions between CXCR4, found on metastatic tumour cells, and CXCL12, 66 
expressed by osteoblasts, MSCs and adventitial reticular cells (Sugiyama, et al. 2006) are a 67 
key component in homing and adhesion of tumour cells to the bone metastatic niche. In the 68 
endosteal niche tumour cells are thought to be held in a quiescent state through 69 
CXCR4/CXCL12 interactions using similar mechanisms to those used by osteoblasts to 70 
maintain quiescence of HSCs (Wang, et al. 2014). Tumour cells hijack mechanisms of HSCs 71 
mobilization and proliferation and form overt metastasis (Ottewell 2016). In addition, the role 72 
of CXCL12 in the primary tumour in the establishment of organ specific metastasis has been 73 
described: Cancer associated fibroblasts (CAFs) in the primary tumour mimic the bone 74 
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marrow microenvironment by producing CXCL12, which has been found to enrich breast 75 
cancer Src hyperactive clones, that survive in the bone marrow (Zhang, et al. 2013). Src is 76 
responsible for mediating breast cancer cell survival in the bone marrow, by controlling 77 
tumour cell response to both pro survival signals in the bone microenvironment like CXCL12 78 
and by conferring resistance to pro apoptotic signals such as TRAIL (Zhang, et al. 2009).  79 
Breast cancer metastasis primarily manifests as a bone lytic disease, however osteolytic, 80 
osteoblastic and mixed lesions occur. In the case of osteolytic metastases, tumour cells 81 
stimulate osteoclast activity and/or inhibit osteoblast differentiation, leading to increased 82 
bone resorption and/or decreased bone formation, respectively, finally resulting in the 83 
development of bone disease and higher risk of fractures. A vicious cycle between breast 84 
cancer cells and bone occurs and sustains the growth of tumour metastases. Growth factors, 85 
produced by osteoblasts, bind the bone matrix. Upon osteoclast mediated resorption growth 86 
factors are released into the local environment where they stimulate tumour cell growth. In 87 
turn, cancer cells themselves alter the function of both osteoblasts and osteoclasts, affecting 88 
bone turnover (Ottewell 2016) (Figure 1). Molecules released by osteoblasts, osteoclasts and 89 
tumour cells during bone turnover have been extensively reviewed in (Le Pape, et al. 2016; 90 
Ottewell 2016; Weilbaecher, et al. 2011) and shown in Figure 1. IL 1B plays a role in bone 91 
homeostasis. Inhibition of IL 1B prevents osteoclastogenesis and osteoblastogenesis, thus 92 
impairing bone resorption and bone formation, respectively (Nakamura and Jimi 2006; 93 
Ruscitti, et al. 2015). IL 1B was shown to be produced by peripheral blood mononuclear cells 94 
(PBMCs) in premenopausal women who underwent ovariectomy and experienced a decrease 95 
in bone mineral density (BMD). Estrogen administration restored IL 1B levels in these 96 
patients, thus suggesting that IL 1B has a major role in bone resorption upon estrogen 97 
withdrawal (Pacifici, et al. 1991). In osteoblastic metastases, tumour cells support 98 
osteoblastogenesis and osteoblast stimulation. In particular, transforming growth factor β 99 
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(TGFB), bone morphogenetic proteins (BMPs) and WNT proteins are known to activate 100 
transcription factors, like RUNX2, that control osteoblast function. It is thought that 101 
metastatic tumour cells release such factors that drive osteoblast formation (Weilbaecher et 102 
al. 2011). Once activated, osteoblasts produce factors such as Interleukin 6 (IL6), monocyte 103 
chemotactic protein 1 (MCP 1), vascular endothelial growth factor (VEGF) and macrophage 104 
inflammatory protein 2 (MIP 2) that sustain cancer growth and interaction with other cells in 105 
the bone microenvironment. Production of CXCL12, BMPs and Notch by osteoblasts sustain 106 
the recruitment of tumour cells in a similar manner to the physiological HSCs recruitment 107 
(Weilbaecher et al. 2011). In osteolytic metastases, TGFB and receptor activator of nuclear 108 
factor kappa B ligand (RANKL) play a major role in driving tumour bone vicious cycle, 109 
whereas BMP, epidermal growth factor (EGF) and platelet derived growth factor (PDGF) 110 
signalling have been found to support this cycle in osteoblastic metastases (Ottewell 2016).  111 
The formation of osteolytic lesions has been associated with extracellular matrix modifying 112 
enzymes, lysyl oxidases (LOXs).  In particular, LOXs are induced in hypoxic conditions in 113 
the primary tumour. Released in the circulation, LOXs travel to the bone where they impair 114 
osteoblast/osteoclast activity. LOXs cause increased bone resorption, by inhibiting osteoblast 115 
activity and increasing osteoclastogenesis. In this LOX regulated environment, where pre 116 
metastatic osteolytic lesions are formed, bone colonisation by breast cancer cells takes place 117 
(Cox, et al. 2015; Sousa and Maatta 2016).  118 
The activity of osteoblasts on bone is directly linked with the maintenance of breast cancer 119 
cell dormancy in this site. We recently showed that ovariectomy induced increase in 120 
osteoclast activity and bone turnover stimulate metastatic breast cancer cells to exit from their 121 
dormant state and start proliferating. When osteoclast activity was reduced in this 122 
ovariectomy model using the RANKL/RANK inhibitor, Osteoprotegerin (OPG), breast 123 
cancer cells disseminated into bone were unable to proliferate into overt metastases and 124 
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remained in a dormant state. (Ottewell, et al. 2015).  A link between IL 1B and OPG has 125 
been recently found in breast cancer primary tumour development and metastasis and will be 126 
discussed later in this Review.  127 
Amongst other cell types present in the bone, osteocytes are considered to play pivotal 128 
functions in maintaining the balance between osteoclast and osteoblast activity during bone 129 
remodeling, by creating a multi functional syncytium through the bone. Osteocytes are 130 
terminally differentiated cells deriving from the osteoblast lineage. Osteoblasts are 131 
surrounded by their released extracellular matrix which forms the osteoid, constituted mainly 132 
by Collagen I. Mature osteoblasts that localise in the osteoid are pre osteocytes. During cell 133 
maturation, the osteoid mineralize and cells that are embedded in it are referred as osteocytes 134 
(Prideaux, et al. 2016). In cancer biology, osteocytes have recently been described as playing 135 
anti cancer functions. Osteocytes use Connexin 43 (Cx43) hemichannels in an intrinsic self 136 
defense mechanism against breast cancer cells colonizing the bone. Cx43 is used by 137 
osteocytes to allow intra  and extra  cellular passage of small molecules. Upon 138 
bisphosphonate treatment, connexin (Cx43) hemichannel opening results in anchorage 139 
independent growth, migration and invasion inhibition of human breast cancer cells. Cx43 140 
osteocyte specific knock out mice and osteocyte specific transgenic mice with impaired Cx43 141 
gap junctions and hemichannels displayed enhanced tumour growth, limiting the anti tumour 142 
effect of bisphosphonate (ZOL) treatment.  Release of ATP from Cx43 hemichannels in 143 
osteocytes was found to mediate anti cancer functions (Zhou, et al. 2016). Despite these 144 
evidence suggest an anti tumour function exerted by osteocytes through Cx43, 
  145 
studies have shown that osteocytes might play also pro tumour functions, when different 146 
breast and prostate cancer cell lines are used. Indeed, breast cancer cell lines treated with 147 
conditioned medium from osteocytes displayed either increased or decreased invasion and 148 
chemotaxis (Cui, et al. 2016). In addition, divergent roles of ATP and adenosine released by 149 
Page 6 of 36
7 
 
osteocytes on breast cancer cells supports the dual role of this bone cell type on breast cancer 150 
bone metastases (Zhou, et al. 2015).  151 
ATP has been identified in the conditioned media of aledronated treated osteocytes as a 152 
factor responsible for breast cancer cell migration inhibition. ATP exerts anti cancer 153 
functions by activating purinergic P2X7 receptor on breast cancer cells. Use of ATP 154 
antagonist (oxidized ATP) or P2X7 knockdown results in reduced cancer inhibitory functions 155 
associated with ATP, whereas the use of BzATP agonist results in breast cancer migration 156 
inhibition 
 . In addition, different ATP dosage correlates with pro  or anti tumour 157 
function. In particular, ATP low dosage inhibits breast cancer cell migration, whereas high 158 
dosage enhances breast cancer cell migration. In the same study, Zhou and colleagues 159 
showed that ATP significantly delays breast cancer primary tumour growth in a xenograft 160 
model. Finally, breast cancer growth in bone was also reduced 
 upon treatment with a 161 
non hydrolysable ATP (ATPγS). Interestingly, upon binding to P2X7R, ATP mediates 162 
NLRP3 inflammasome dependent IL 1B secretion (Karmakar, et al. 2016). Considering that 163 
IL 1B is a prognostic marker for breast cancer disease progression, it is puzzling to define a 164 
pro  or –anti tumour function for the energy carrying molecule.  165 
Alongside bone, the adipose tissue present also supports breast cancer metastasis in this 166 
secondary site. During aging, adipose tissue increases in bone and, simultaneously, enhanced 167 
breast cancer metastasis can be observed. Breast cancer cells establish contacts with 168 
adipocytes when in co culture with cancellous bone fragments of human origin and increase 169 
their migratory properties. The analysis of conditioned medium derived from human bone 170 
tissue identified high levels of IL 1B (Templeton, et al. 2015). 171 
More recent advances in the understanding of tumour microenvironment interactions have 172 
elucidated the crucial role of the immune system in either supporting or inhibiting cancer 173 
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progression. Tumour associated macrophages (TAMs) have been found to infiltrate primary 174 
breast cancer. Previously classified in M1 (classically activated macrophages with anti cancer 175 
functions) and M2 (alternatively activated macrophages with pro tumour functions), 176 
macrophages are now grouped in four categories: M1 (IFNy/LPS), involved in inflammation, 177 
microbial killing and anti tumour functions, M2a (IL4/IL13) involved in allergic reactions, 178 
intracellular parasite killing and matrix remodeling, M2b (immunocomplexes) associated 179 
with immunoregulation and suppression of inflammation and M2c (IL10) responsible for 180 
Treg stimulation, immunosuppression and matrix remodeling. TAMs generally have an M2 181 
phenotype. In breast cancer, high density of TAMs associates with poor prognosis. TAMs 182 
support tumour angiogenesis, invasion by remodeling of the tumour extracellular matrix, 183 
mechanisms of immune evasion, infiltration of immunosuppressive leukocytes and activation 184 
of breast cancer stem cells (as reviewed by Choi J. et al. 2018 (Choi, et al. 2018)). Moreover, 185 
in the context of tumour relapse after chemotherapy, MRC1
hi
, CXCR4
hi
, Tie2
hi
 VEGFA
+
 186 
macrophages have been identified as tumour supporting M2 macrophages localising in 187 
perivascular areas where CXCL12 is expressed. These are perivascular macrophages that 188 
stimulate tumour relapse after chemotherapy (Hughes, et al. 2015). Tumour infiltrating 189 
macrophages can derive from circulating monocytes (formed in the bone marrow) or tissue 190 
resident macrophages (embryonal origin). The role of bone marrow resident macrophages 191 
(Osteomacs) is currently under investigation. So far, indirect evidence allows to speculate 192 
that metalloprotease (MMP9) and M CSF (Macrophage Colony Stimulating Factor) levels in 193 
breast cancer cells (MDA MB 231) correlate with TAM infiltration and osteomac 194 
polarization (Sousa and Maatta 2016). Monocytes and macrophages can differentiate into 195 
osteoclasts by the combination of RANKL and M CSF. Additional stimulation with 196 
cytokines involved in M1/M2 polarisation has been found to either promote or impair 197 
macrophage differentiation into osteoclasts (Jeganathan, et al. 2014). Therefore, 198 
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understanding the balance between macrophage and osteoclast polarisation in bone could 199 
provide new insights in breast cancer bone metastases. 200 
Interestingly, breast cancer cells have been found to modulate the hematopoietic stem cell 201 
niche by modulating the CXCL12 CXCR4 signalling axis. In particular, CXCL12 levels in 202 
bone marrow derived mesenchymal stromal cells were found to be lower upon treatment with 203 
medium derived from breast cancer cells or in co culture conditions. CXCL12 204 
downregulation affected HSPCs migration towards MSC/cancer cells co culture or 205 
conditioned medium (Wobus, et al. 2015). Furthermore, the cross talk between MSCs and 206 
cancer cells relates to CDH1 (E cadherin) and IL 1B levels. High CDH1 and low IL 1B in 207 
cancer cells induce MSC organization into a niche like formation, dependent on direct cell 208 
cell contact, 
 (Al toub, et al. 2015). 209 
It has been hypothesised that metastatic cancer cells compete with HSCs to colonise their 210 
niche in bone. Evidence from prostate cancer show that CXCL12 CXCR4 signalling is 211 
involved in the niche colonisation by tumour cells and competition with HSCs. Once in bone, 212 
dormant tumour cells are exposed to a microenvironment that generally maintain HSCs in a 213 
quiescent state. This microenvironment is hypoxic and populated by stromal cells that 214 
produce anti apoptotic and pro survival signals (Ren, et al. 2015). Therefore, tumour HSC 215 
interaction mainly contributes to tumour dormancy. 216 
	
217 
	
218 
The IL 1 type cytokine family comprises seven molecules with agonist functions, including 219 
IL 1B and IL 1A, three receptor antagonists and one anti inflammatory cytokine. Evolution 220 
studies have shown that, starting from fish, vertebrates have a single IL 1 gene (Ogryzko, et 221 
al. 2014). IL 1 cytokines bind to IL 1R receptors. There are eleven IL 1R receptors. IL 1B 222 
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and IL 1A are encoded by distinct genes and bind both to IL 1R1, found on nearly every cell, 223 
and IL 1R2 (Garlanda, et al. 2013). IL 1A is also known as alarmin and it can be found in 224 
homeostatic conditions. IL 1A precursor is constitutively present in several epithelial layers 225 
and it is already active when released upon cell necrosis. IL 1A mediates the early phases of 226 
sterile inflammation by rapidly inducing a cascade of several cytokines and chemokines. 227 
Differently from IL 1A, IL 1B is not present in homeostatic conditions. IL 1B plays its main 228 
role as “gatekeeper” of inflammation. IL 1B is mainly produced by blood monocytes, tissue 229 
macrophages, skin dendritic cells and brain microglia (Garlanda et al. 2013). IL 1B synthesis 230 
occurs upon stimulation by Pattern Associated Molecular Patterns (PAMPs), whereas its 231 
activation is linked to secondary stimuli, such as Damage Associated Molecular Patterns 232 
(DAMPs), in presence of invading pathogens and upon sterile danger signals (Baroja Mazo, 233 
et al. 2014) (Brough, et al. 2011). IL 1B is processed by the inflammasome, a multi protein 234 
complex activated via NOD like receptor (NLR) family, pyrin domain containing proteins 235 
(NLRPs) and required for the activation of Caspase 1, needed for IL 1B cleavage and 236 
activation (Li, et al. 1995; Miller, et al. 1993) (Figure 2). Caspase 1 mediated pyroptosis is a 237 
lytic form of cell death and an innate immune effector mechanism. During inflammation, 238 
after Caspase 1 mediated cleavage and activation, IL 1B is released in a still poorly 239 
understood “unconventional” secretory manner (Vince and Silke 2016). A simple hypothesis 240 
suggests that activated IL 1B is passively released after Caspase 1 induced pyroptosis, 241 
underlining the link between cell death and inflammation. In addition, the role of gasdermins 242 
D (GSDMD) proteins in inducing pyroptosis, upon inflammatory caspase cleavage, has been 243 
recently described and suggested that their pore forming function during pyroptosis is needed 244 
for IL 1B secretion after maturation (Ding, et al. 2016). As gasdermins play an important role 245 
in the induction of pyroptosis, this type of cell death has been renamed as gasdermin 246 
mediated programmed necrosis, characterised by osmolitic potential disruption and 247 
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consequent cell lysis (Shi, et al. 2017). The formation of gasdermin mediated pores allows 248 
IL 1B secretion even when a cell is still intact and functional, restricting the passage of larger 249 
molecules and organelles. Importantly, after pore formation, cells can shut down the 250 
inflammasome, allowing IL 1B release while preventing pyroptosis, therefore explaining 251 
how IL 1B secretion can occur even without cell death (Kovacs and Miao 2017). Pyroptosis 252 
occurs also in non immune cells, where is characterised by the activation of other caspases 253 
(11/4/5), which do not cleave IL 1B (Shi et al. 2017). Alongside Caspase 1 mediated 254 
pyroptosis, active release of IL 1B has also been described, via secretory lysosomes, 255 
multivesicular bodies and direct micro vesicular shedding (Vince and Silke 2016). Once 256 
cleaved and released, IL 1B binds to its correspondent receptor, IL 1R1, which can also be 257 
recognised by IL 1A and the antagonist (IL 1RA). However, differently from IL 1A and IL 258 
1B, IL 1RA does not trigger downstream signalling activation upon binding to IL 1R1 259 
(Weber, et al. 2010). Together with IL 1RA, IL 1R2 (decoy receptor) and the “shed” 260 
domains of each extracellular IL 1 receptor chains function as negative regulators of IL 1 261 
signalling. IL 1R1 and IL 1R2 share high similarity and their extracellular domains are 262 
members of the immunoglobulin superfamily, each comprising three IgG like domains. The 263 
extracellular domains of IL 1R1 and IL 1R2 can be found also as soluble forms. IL 1R has a 264 
single transmembrane domain and a cytoplasmic domain and is the main receptor that 265 
transduces downstream signalling (Dinarello 1997). IL 1 signalling activation occurs upon 266 
binding to the IL 1R1 receptor and consequent conformational change of the extracellular 267 
domain. Further recruitment of IL 1RacP (IL 1R associated protein) and activation of 268 
cytosolic Toll  and IL 1R like domains results in the recruitment of Myd88 (myeloid 269 
differentiation primary response gene 88) and IRAK4 (Interleukin 1 receptor associated 270 
kinase 4). IRAK4 undergoes autophosphorylation and causes the phosphorylation of IRAK1 271 
and IRAK2, with following recruitment of TRAF6 (TNF receptor associated factor). 272 
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IRAK1/2 and TRAF6 dissociate from the receptor complex and activate nuclear factor kappa 273 
light chain enhancer of activated B cells (NFkB). Once in the nucleus NFkB acts as a 274 
transcription factor for inflammatory genes, such as IL 6, IL 8, MCP 1 and cyclooxygenase 2  275 
(COX 2) (Weber et al. 2010) (Figure 2).  276 
	
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277 
Human cancerous breast tissue expresses IL 1B. Recent evidence from our group have shown 278 
that breast cancer cells with increased ability to metastasise in bone (MDA IV) display higher 279 
IL 1B expression, compared to its correspondent parental line, suggesting that IL 1B 280 
expression correlates with enhanced metastatic potential (Nutter et al. 2014). 281 
A positive correlation between IL 1B expression, OPG and CCL2 have been found in human 282 
breast cancer genome wide mRNA expression array. OPG belongs to the TNF Receptor 283 
Superfamily, it functions as a decoy receptor during bone resorption and affects TRAIL 284 
mediated apoptosis. Inhibition of OPG in breast cancer cell lines showed reduced invasion 285 
and metastasis. In particular, IL 1B upregulates OPG via p38 and p42/22 MAPK signalling 286 
pathway and induces OPG secretion, which associate also with macrophage infiltration in 287 
primary breast tumours. Co culture of IL 1B secreting macrophages and breast cancer cells 288 
results in enhanced OPG secreted by tumour cells (Chung, et al. 2017). Taken together these 289 
data suggest a role of IL 1B and OPG in mediating breast cancer metastasis and 290 
inflammation. Data shown above suggest that OPG has the potential to act as both a pro or 291 
anti tumour molecule dependent on whether the tumour is at its primary or metastatic site and 292 
if OPG is produced by tumour cells or by the cells in the microenvironment. Whether anti 293 
tumour effects are specific to the bone microenvironment remain to be elucidated. OPG, 294 
mainly expressed by osteoblasts, is a decoy receptor and is a natural inhibitor of 295 
osteoclastogenesis (through inhibition of RANKL/RANK signalling) (Boyce and Xing 2008; 296 
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Le Pape et al. 2016). This potentially explains its anti tumour effect in bone. In addition to 297 
playing a role in tumour growth, IL 1B has been reported to control tumour invasion. "
 298 
evidence from MCF7 breast cancer cells suggests that this may, in part, be due to, IL 1B 299 
regulating breast cancer cell invasion by stimulating production of MMP 9 via Focal 300 
Adhesion Kinase 1 FAK and the proto oncogene tyrosine protein kinase Src (Mon, et al. 301 
2017).  302 
IL 1B and IL 1A may both play roles in tumour formation and progression to metastasis. IL 303 
1B has been linked with poor prognosis in breast cancer (Nutter et al. 2014), whereas, 304 
tumour induced IL 1A has been linked to CCL22 production by tumour infiltrating immune 305 
cells. CCL22 is known to induce the recruitment of T regulatory (Treg) cells. Inhibition of 306 
IL 1R1 signalling using Anakinra has been found to impair Treg migration (Wiedemann, et 307 
al. 2016).   In the same study, the authors also showed that as a result of silencing IL 1A in 308 
pancreatic tumour cells (PaTu), CCL22 production was inhibited in PBMC, whereas 309 
inhibition of IL 1A or IL 1B in mammary 4T1 cancer cell line resulted in impaired CCL22 310 
production in splenocytes. In addition to promoting tumour progression, by controlling Treg 311 
recruitment via CCL22 signalling, however, IL 1A mediated IL 1R1 signalling has also been 312 
reported to have anti tumour functions. In particular, using a spontaneous murine mammary 313 
tumour model (MMTV PyMT), Dagenais and colleagues have shown that IL 1R1 signalling 314 
suppresses mammary tumour cell proliferation early in tumorigenesis and reduces breast 315 
cancer outgrowth and metastasis in the lungs. High primary tumour burden was found in both 316 
IL 1R1  /  and IL 1A  /  mice and this phenotype was independent of Caspase 1/ 11 317 
(Dagenais, et al. 2017). Hence, IL R1 signalling could have both pro  and anti tumour 318 
functions and it is possible that IL 1A and IL 1B may exert opposite functions in breast 319 
cancer progression. 320 
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The murine spontaneous mammary tumour model MMTV PyMT has been employed to 321 
investigate the role of IL 1 and the inflammasome in primary mammary tumour growth and 322 
pulmonary metastasis, alongside allograft and xenograft models of breast cancer. For this 323 
purpose, mice lacking functional Caspase 1 and NLRP3 in combination with 324 
pharmacological treatment to inhibit IL 1R were employed. Inhibition of the inflammasome 325 
and IL 1 signalling resulted in reduced primary tumour growth, lung metastasis and myeloid 326 
cell infiltration (Guo, et al. 2016).  327 
The data above fit with our recent findings in which we showed that IL 1 associates with 328 
primary tumour development of human mammary tumours 
 . Pharmacological 329 
inhibition of IL 1R with Anakinra before subcutaneous injection of either triple negative 330 
MDA 231 IV or ER+ve MCF 7 cells significantly reduced tumour formation, whereas, 331 
treatment of established tumours with Anakinra significantly reduced tumour cell 332 
proliferation. (Figure 3) These data suggest that inhibition of IL 1R signalling impairs breast 333 
cancer progression from both ER ve and ER+ve tumours (Holen, et al. 2016a). 334 
IL 1B has been shown to have profound effects on tumour growth and metastasis in tumour 335 
types other than breast cancer, including melanoma. A reduction of local tumours or lung 336 
metastasis was found in mice lacking functional IL 1R signalling (IL 1B KO), together with 337 
diminished tumour angiogenesis. Similar results on angiogenesis was also found upon IL 1R 338 
pharmacological inhibition.  IL 1A KO mice displayed also a reduction in melanoma growth 339 
and angiogenesis compared to WT animals, but the effect was less evident when compared to 340 
IL 1B KO mice, suggesting a major role of IL 1B. The findings could be extended to 341 
mammary and prostate cancer models (Voronov, et al. 2003).  342 
	
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Tumour angiogenesis is a hallmark of cancer and IL 1 is a strong endothelial cell (EC) 344 
activator. IL 1 enhances pro inflammatory responses, angiogenesis, growth rate, migration, 345 
morphological changes, contact inhibition and permeability of ECs. IL 1B up regulates 346 
VEGF and its correspondent receptor on ECs and via IL 1R1 causes EC migration and tube 347 
formation by activating p38 MAPK and MAPK activated protein kinase 2. Moreover, IL 1 348 
has been described to synergise with VEGF and overlapping gene signatures have been 349 
identified in ECs, particularly for genes involved in cell growth and inflammation. In a 350 
matrigel model, abrogation of rVEGF or rIL 1B resulted in an abolished angiogenic response.  351 
Administration of rVEGF to mice with impaired IL 1B signalling resulted in reduced neo 352 
angiogenic response in matrigel plugs (Carmi, et al. 2013). There is considerable interest in 353 
using anti angiogenic therapy, however, the results from clinical trials have been 354 
disappointing due to tumours rapidly developing resistance mechanisms to these drugs. The 355 
tumour microenvironment plays a large role in resistance to anti angiogenic drugs with 356 
immune cells being a predominant source of angiogenic factors. Consequently, there are now 357 
a multitude of studies looking at the effect of combinatorial treatments to block angiogenesis 358 
as well as to modify immune cell response to improve the efficacy of anti angiogenic 359 
therapy. Inhibition of IL 1B impairs the recruitment of immune cells at cancerous sites, 360 
limiting the production of pro angiogenic molecules. IL 1Ra has been found to inhibit the 361 
angiogenic response, concomitantly inhibiting tumour progression. We recently showed that 362 
IL 1R1 antagonist Anakinra reduces the number of microvessels in sub cutaneous breast 363 
tumours and bone metastases caused by the osteotrophic triple negative breast cancer cell line 364 
MDA MB 231 IV, after both a preventative and treatment strategy (Figure 3) (Holen et al. 365 
2016a). Therefore, IL 1 signalling inhibition in combination with anti angiogenic therapies 366 
could represent the way forward to limit tumour progression (Voronov et al. 2003).  367 
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IL 1B signalling and inflammation are strongly connected and inflammation plays a major 369 
role during cancer progression. In particular, the fine balance between IL 1B and IL 1Ra 370 
activity is important to control inflammation: IL 1B and IL1R1a overexpression results in an 371 
enhanced and reduced inflammatory state, respectively.  372 
In bone inflammatory diseases like rheumatoid arthritis, enhanced inflammation and 373 
osteoclast differentiation and activation have been reported. In this condition, enhanced 374 
infiltration of macrophages, which are a primary source of pro inflammatory cytokines, 375 
causes bone damage (Funk, et al. 1998; Okano, et al. 1996). In addition, IL 1B produced by 376 
macrophages and T cells increases osteoclastogenesis, by regulating osteoclast progenitors 377 
(Strand and Kavanaugh 2004). Because IL 1B regulates bone homeostasis and contributes to 378 
enhanced bone resorption upon inflammation, it is possible to speculate that in breast cancer 379 
metastasis, IL 1B alters bone turnover in favor of the vicious cycle (figure 1). The 380 
mechanism by which IL 1B produced by different cell types promotes metastasis is still 381 
under investigation. 382 
Immune cells also play a pivotal role in cancer and inflammation. Mice lacking IL 1R display 383 
delayed myeloid derived suppressor cell (MDSC) infiltration and reduced primary breast 384 
tumour development, a phenotype that is restored by IL6. Conversely, mice with a non 385 
functional IL 1Ra display enhanced inflammation, characterised by a more rapid 386 
accumulation of MDSCs in breast tumour. This finding suggest that inflammation supports 387 
tumour progression by enhancing immune suppressive mechanisms (Bunt, et al. 2007). "
388 
 studies have recently shown that primary breast cancer cells co cultured with monocytes 389 
display increased IL 1B, IL8 and MMPs (Espinoza Sanchez, et al. 2017), suggesting that 390 
inflammation and therefore the recruitment of immune cells support the development of 391 
breast cancer during the early stages. In addition, pro inflammatory effects of IL 1B also 392 
promotes metastasis: In a spontaneous 
  model of breast cancer, tumour cells induce 393 
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systemic inflammation by producing IL 1B, which stimulates IL 17 production by γδ T cells. 394 
Subsequently, IL 17 drives the production of G CSF that causes neutrophil expansion and 395 
polarization towards a CD8+ T cell suppressive phenotype via iNOS, enhancing immune 396 
suppression and distant metastases (lung and lymph nodes) (Coffelt, et al. 2015). IL 1B is 397 
also involved in the mobilisation of myeloid derived suppressor cells further promoting both 398 
primary and metastatic breast tumours (Karki, et al. 2017). 399 
Finally, NLRP3 IL 1B IL1R signalling has been shown to control NK and T cells, by 400 
inhibiting their tumouricidal potential and inhibiting the anti tumour effect of 401 
chemotherapeutic agents by inducing the secretion of IL17 by CD4+ T cells (Karki et al. 402 
2017). The IL 1B driven detrimental role of the inflammasome in cancer opposes to its 403 
protective role, mainly driven by IL 18, as reviewed in (Karki et al. 2017). 404 
 	
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Expression of IL 1B by primary breast cancer cells strongly correlates with disease re 406 
occurrence and future relapse in bone: In tissue arrays containing 150 primary tumour 407 
biopsies taken from patients newly diagnosed with stage II/III breast cancer enrolled onto the 408 
AZURE trial, 49% of patients with detectable IL 1B in their tumours experienced relapse 409 
compared with 7% of patients with IL 1B negative tumours and 37% of patients with 410 
detectable IL 1B in their primary tumours developed bone metastasis compared with 5% of 411 
patients with IL 1B negative tumours over an 84 month time period (Coleman, et al. 2011). 412 
In addition, breast cancer cell lines that specifically home to and colonise mouse bone 413 
(MDA IV) have been shown to express high levels of IL 1B (Nutter et al. 2014). We have 414 
recently shown that inhibiting IL 1R signalling, using the receptor antagonist Anakinra, 415 
results in decreased breast cancer bone metastases (Figure 3). Administration of Anakinra 416 
before injection of tumour cells did not prevent numbers of tumour cells that arrived in the 417 
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bone environment, but held these tumour cells in a dormant state, significantly inhibiting 418 
development of both micro metastases and overt metastases. When Anakinra was given 1 419 
week after tumour cell inoculation these existing bone metastases ceased to grow and this 420 
appeared to be the result of reduced proliferation and reduced angiogenesis, whereas 421 
apoptotic cell death remained unaltered. Because of the tight coupling between tumour cells 422 
and bone cells that occurs in bone metastases, the effects of IL 1B on the bone environment 423 
may also play important roles in this process. In tumour naïve mice, a single dose of 424 
Anakinra reduces osteoclast and osteoblast activity in addition to causing a reduction in IL 425 
1B and TNFa levels indicating that in addition to anti tumour effects of Anakinra this drug 426 
may also target bone cells thus reducing resorption and availability of bone derived grow 427 
factors that can further stimulate tumour growth. These Anakinra induced alterations to the 428 
bone environment were maintained following continuous administration of Anakinra for >21 429 
days and this treatment did not cause significant effect on trabecular bone volume. Taken 430 
together these data suggest that Anakinra could be re purposed as a treatment of bone 431 
metastatic breast cancer (Holen et al. 2016a).  432 
As evidenced above blocking IL 1R activity with Anakinra holds disseminated tumour cells 433 
in a dormant state in the bone environment. Recent 
 data indicate that IL 1B and not 434 
IL 1A is the relevant cytokine linked to dormancy of breast cancer cells in this environment. 435 
Co culture of a human breast cancer cell line, with suppressed ability to form metastases, 436 
with osteoblasts resulted in faster growth of breast cancer cells attached to the matrix made 437 
by the osteoblasts when stimulated with IL 1B and TNFa. Interestingly, the IL 1B and TNFa 438 
stimulated growth was suppressed when COX2 activity or PGE2 receptor were blocked, in 439 
line with data showing that IL 1B and TNFa activate the arachidonic acid pathway (Mark, et 440 
al. 2001; Ono 2008; Sosnoski, et al. 2015).  441 
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MSCs play a pivotal role in bone metastases as their niche overlaps with the cancer stem cell 442 
niche in this environment. How breast cancer cells, chemokines and cytokines, including IL 443 
1B affect these cells may be a fundamental factor in determining whether tumour cells in 444 
bone are able to progress to overt metastases. Exposing MSCs to conditioned media derived 445 
from metastatic breast cancer cells resulted in increased levels of chemokines, such as 446 
CXCL1, 3, 5, 6, 8, CCL2 and CCL7. Importantly, chemokine expression was inhibited in 447 
MSCs exposed to conditioned media derived from metastatic breast cancer cells treated with 448 
NFKB inhibitor. Interestingly, amongst NFKB downstream targets, IL 1B has been identified 449 
as a major regulator of chemokine production in MSCs. IL 1B was present in the supernatant 450 
of metastatic breast cancer cells. When treated with IL 1B, MSCs were found to upregulate 451 
the same cytokines that were observed following exposure to cancer cell conditioned media. 452 
Inhibition of IL 1B in metastatic breast cancer cells resulted in no chemokine production by 453 
MSCs, whereas overexpression of IL 1B in non metastatic breast cancer cells increased 454 
chemokine levels in MSCs. Therefore, IL 1B is a major candidate in driving the production 455 
of chemokines in the tumour microenvironment, which, in turn, sustain tumour development 456 
(Escobar, et al. 2015). 457 
!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The majority of mouse models that are used to study bone metastasis involve injecting MDA 459 
MB 231 cells (breast) or PC3 (prostate) and their bone homing derivatives directly into the 460 
left cardiac ventricle from where the cells become disseminated in the skeleton (Nutter et al. 461 
2014; Ottewell, et al. 2010; Ottewell, et al. 2014a; Ottewell, et al. 2014b). Although this 462 
method does not mimic the early stages of the metastatic process consisting of growth at the 463 
primary site and dissemination into the circulation, human breast cancer cell lines do not 464 
spontaneously metastasise from the fat pad to the mouse skeleton without oestradiol 465 
supplementation.  Although oestrogen receptor positive breast cancer cell lines, MCF7 and 466 
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T47D reliably metastasise from mouse mammary fat pads to mouse long bones in ~90% of 467 
animals when mice are supplemented with oestradiol, it is hypothesised that metastasis to 468 
bone is driven by the bone anabolic effects of oestradiol (Holen, et al. 2016b), as IL 1B also 469 
affects bone turnover data obtained using these model systems would need to be interpreted 470 
with this in mind (Holen et al. 2016a). For more basic experiments designed to investigate 471 
tumour growth in bone and tumour cell bone cell interactions, it is possible to inject most 472 
cancer cell lines directly into the tibiae or femur. It must be noted, however, that this method 473 
does not model tumour cell dissemination into the bone metastatic niche, tumour cells grow 474 
randomly within the marrow cavity from direct injection into bone and bone healing occurs in 475 
conjunction with tumour induced lesion formation, complicating data analysis (Wright, et al. 476 
2016) 477 
The growth of human cancer cells in mice requires the use of immunocompromised mice 478 
negating the role of the immune system. This may be especially important when studying the 479 
effects of a pro inflammatory cytokine such as IL 1B. Intra cardiac or intra mammary 480 
injection of mouse mammary 4T1 cells results in metastasis to lung, liver, brain and bone and 481 
bone homed derivatives including 4T1.1 have increased bone homing capacities. Many 482 
researchers report increased metastasis following removal of the mammary tumour (Francia, 483 
et al. 2011). The use of syngeneic models is an excellent tool to study the interaction between 484 
tumour cells and the microenvironment primarily because these animals have a fully 485 
competent immune system.  486 
The use of breast cancer cell lines to model cancer development and progression has been 487 
heavily criticised due to these cells having been cultured in the laboratory for numbers of 488 
years leading to culture adaptation and loss of heterogeneity. This has led to the development 489 
of mouse models of metastasis utilising patient derived tumours. Surgical implantation of 490 
patient derived xenografts (PDX) orthotopically into mice has been successfully used to study 491 
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bone metastasis from prostate, breast and lung cancer, as well as other metastatic sites for 492 
different cancer types (i.e. lymph node and liver metastasis for colon cancer and metastatic 493 
pancreatic, stomach, ovarian, bladder and kidney cancer) (Hoffman 1999). Tumour cells 494 
behave differently according to the microenvironment in which they are seeded. Orthotopic 495 
models offer significant advantages over subcutaneous models as they more accurately model 496 
interactions between tumour cells and organ specific microenvironments, allowing to study 497 
the behaviour of human tumours in the tissue from which they originate. Environmental 498 
signals prime tumours in the primary site to metastasise to specific organs, therefore, in order 499 
to accurately study organ specific tropism of metastasis, orthotopic implantation of tumour 500 
cells may be necessary. However, bone metastasis from these models are rare and growth of 501 
patient derived material requires oestradiol supplementation, and the bone anabolic effects of 502 
oestradiol need to be taken into account when interpreting data from these models. 503 
Other PDX models have been developed to address different questions related to the biology 504 
of cancer. PDX allows to study intra  and inter  tumour heterogeneity and how this affects 505 
response to therapy. PDX models can be used to study primary or acquired resistance to 506 
drugs by engrafting patient derived material that has been isolated from patients before or 507 
after therapy, respectively. Clinical trial associated xenografts (CTAXs) are a form of PDX 508 
model that has the potential to be used in personalised medicine, as biopsies taken from 509 
patients during clinical trials, at different stages of treatment and disease progression. 510 
Generally, PDX models use immunocompromised animals to allow engraftment of human 511 
tissues. Originally, patient derived xenografts to study metastatic breast cancer were 512 
developed in nude mice (Fu, et al. 1993), whereas today there is a conscious move to using 513 
murine models of NOD SCID Gamma mice which have been engrafted with human immune 514 
cells. In this model, total peripheral blood or bone marrow from healthy donors or patients is 515 
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injected into the tail vein of young animals in order to consider the contribution of the 516 
immune system in tumour progression.  517 
There are a number of mouse models that can be used to study different stages of the bone 518 
metastatic process from different tumour types. Each model has its pros and cons and data 519 
obtained from these models should be interpreted with specific limitations in mind. There is 520 
an ongoing effort to make more clinically relevant mouse models of bone metastasis and a 521 
complete review on how to set up and utilize these models can be found in Wright, et al. 2016 522 
(Wright et al. 2016). 523 
 "	
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 524 
IL 1B is an inflammatory molecule and targeted therapies have been developed to treat 525 
chronic inflammation and auto inflammatory diseases. IL 1 signalling inhibition was first 526 
achieved using Anakinra, a recombinant form of the naturally occurring IL 1 receptor 527 
antagonist. Originally introduced in 2001 to treat rheumatoid arthritis (Dinarello, et al. 2012), 528 
Anakinra has been recently proposed as a potential treatment for pericarditis and 529 
cardiovascular complications occurring during Diabetes Mellitus (Peiro, et al. 2017). It is 530 
currently clinically indicated for the treatment of inherited auto inflammatory diseases 531 
associated with non functional NLRP3 and ILRN cryopirin associated periodic syndromes 532 
(CAPS) (Jesus and Goldbach Mansky 2014). Alongside Anakinra, Rilonacept (soluble decoy 533 
receptor) and Ilaris (or Canakinumab, a neutralizing anti IL 1B IgG1 antibody) are the drugs 534 
currently used in the clinical practice to target the IL 1 signalling pathway (Peiro et al. 2017). 535 
As shown in Table 1, Anakinra is currently in clinical trials for metastatic breast cancer 536 
(	
, metastatic colorectal cancer (
, pancreatic adenocarcinoma 537 
(	
, multiple myeloma and plasma cell neoplasm (
. It is used 538 
alone or in combination with chemotherapeutic agents (Gemcitabine, Nab Paclitaxel, 539 
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Cisplatin) (	
, anti resorptive agents (Denosumab, anti RANKL monoclonal 540 
antibody) (	
, mTOR inhibitor (Everolimus) (	) and Lenalidomide 541 
and Dexamethasone (	) (early stages multiple myeloma). A clinical trial for 542 
colorectal cancer, triple negative breast cancer, NSCLC and adenocarcinoma in Phase 1 is 543 
currently recruiting participants to test the checkpoint inhibitor PDR001 in combination with 544 
other immunomodulatory agents, including Ilaris (NCT02900664). The results of these 545 
clinical trials will be awaited with interests and they will provide valuable information on the 546 
use of Anakinra and Ilaris used alone or in combination with other therapeutic regimes to 547 
treat cancer patients. 548 
#$549 
Bone is a preferential metastatic site for breast cancer. IL 1B has been identified as 550 
biomarker that can be used to predict which breast cancer patients are likely to experience 551 
relapse in bone. "
 studies have suggested so far that IL 1B correlates with increased 552 
aggressiveness of breast cancer cell lines. Although 
 studies are in their infancy, those 553 
that have been carried out confirm these findings. In particular, we have shown that IL 1 554 
signalling is linked to breast cancer metastasis specifically to bone. The inhibition of IL 1R1 555 
and reduced bone metastasis in our mouse model shows the role of this signalling axis in 556 
breast cancer metastasis to bone, but further studies are needed to elucidate whether IL 1B 557 
and/or IL 1A are primarily involved in this process.  558 
The combination of anti angiogenic therapies and immune therapies represent a new strategy 559 
to treat tumours that develop resistance to standard of care treatments and/or anti angiogenic 560 
therapy alone. Intra tumoural myeloid cells have been found to regulate responsiveness and 561 
resistance to anti angiogenic therapies (Rivera, et al. 2015). IL 1B is the gatekeeper of 562 
inflammation. It is produced mainly by immune cells, challenged by invading pathogens and 563 
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danger signals and has been found to exert angiogenic functions. Therefore, inhibiting IL 1B 564 
signalling is a potential new therapeutic strategy to simultaneously block angiogenesis and 565 
dampen inflammation, impairing breast cancer bone metastasis. The availability of safe and 566 
approved therapeutic strategies targeting IL 1 signalling such as Anakinra and Ilaris could 567 
facilitate the treatment of patients affected by breast cancer driven bone disease. 568 
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Treatment Cancer type 
Clinical Trial 
identifier 
Clinical Trial 
Phase 
Anakinra and standard of care Metastatic breast cancer NCT01802970 Phase I 
Anakinra and Bevacizumab Metastatic colorectal cancer NCT02090101 Phase II 
Gemcitabine, Nab-Paclitaxel, Cisplatin 
and Anakinra 
Pancreatic adenocarcinoma NCT02550327 Early Phase I 
Anakinra alone or with Dexamethasone 
Multiple myeloma 
Plasma cell neoplasm 
NCT00635154 Phase II 
Anakinra or Denosumab and Everolimus Advanced cancers NCT01624766 Phase I 
Lenalidomide and Dexamethasone with 
or without Anakinra 
Indolent plasma cell myeloma 
Plasma cell myeloma  
Smoldering Plasma cell 
myeloma) 
NCT02492750 
Phase I, 
followed by 
Phase II 
PDR001 in Combination with CJM112, 
EGF816, Ilaris® (Canakinumab) 
or Mekinist® (Trametinib) 
Colorectal Cancer, Triple 
Negative Breast Cancer, 
NSCLC, Adenocarcinoma 
NCT02900664 
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